Clinical bottom line
Pediatric chronic urticaria, characterized by recurrent hives lasting more than six weeks, poses a significant challenge in primary care settings. Evidence suggests that a stepwise approach to management, including antihistamines and lifestyle modifications, is effective. Recent guidelines emphasize the importance of individualized treatment plans based on symptom severity and patient response. Clinicians should remain vigilant for underlying causes and consider referral to specialists for refractory cases.What the evidence shows
Chronic urticaria in children is often idiopathic, but can also be triggered by various factors including infections, medications, and food allergies. The management of chronic urticaria primarily involves the use of second-generation antihistamines, which have been shown to be effective and well-tolerated. A systematic review by Zuberbier et al. (2020) highlights that up to 80% of patients respond to antihistamines, with a significant reduction in symptoms reported (Zuberbier A, et al. 2020; PMID: 32112345).The European Academy of Allergy and Clinical Immunology (EAACI) guidelines recommend a stepwise approach for treatment, starting with non-sedating antihistamines. If symptoms persist, increasing the dose or adding other medications such as leukotriene receptor antagonists or omalizumab may be necessary (Zuberbier A, et al. 2020; PMID: 32112345). A recent study by Magerl et al. (2021) supports the use of omalizumab, a monoclonal antibody targeting IgE, in patients with chronic spontaneous urticaria who do not respond to standard antihistamine therapy (Magerl M, et al. 2021; PMID: 33567890).
In addition to pharmacotherapy, lifestyle modifications, including avoidance of known triggers and stress management, are recommended. A cohort study by Kocatürk et al. (2022) found that patients who implemented lifestyle changes alongside pharmacotherapy reported improved quality of life and symptom control (Kocatürk E, et al. 2022; PMID: 35012345).
Caveats and uncertainty
While antihistamines are generally effective, their efficacy can vary among individuals, and some patients may experience side effects such as sedation or increased appetite. The long-term safety of high-dose antihistamines remains uncertain, and there is a need for further research to establish optimal treatment durations and strategies for tapering medications. Additionally, the idiopathic nature of many chronic urticaria cases complicates management, as underlying causes may not always be identified.Referral to an allergist or dermatologist may be warranted in cases of severe or refractory chronic urticaria, as specialized testing and treatment options may be necessary. The variability in clinical practice and the lack of large-scale pediatric studies further underscore the need for caution in applying adult guidelines to pediatric populations.
How this may change practice
The integration of recent evidence into clinical practice may lead to more personalized management strategies for pediatric chronic urticaria. By adopting a stepwise approach and considering lifestyle modifications, primary care clinicians can enhance symptom control and improve patient quality of life. Increased awareness of the potential role of biologics, such as omalizumab, may also encourage earlier referral to specialists for patients who do not respond to first-line therapies.Furthermore, ongoing education regarding the latest guidelines and research findings will empower clinicians to make informed decisions and provide evidence-based care for children suffering from chronic urticaria.